Protein kinase Cδ negatively regulates Notch1-dependent transcription via a kinase-independent mechanism in vitro  by Kim, Minsoon et al.
Biochimica et Biophysica Acta 1823 (2012) 387–397
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrProtein kinase Cδ negatively regulates Notch1-dependent transcription via a
kinase-independent mechanism in vitro
Minsoon Kim a, Ji-hyun Ju a, Kibeom Jang a, Sunhwa Oh a, Jieun Song a, Chul Geun Kim a, Incheol Shin a,b,⁎
a Dept. of Life Science, Hanyang University, Seoul 133-791, Republic of Korea
b Natural Science Institute, Hanyang University, Seoul, 133-791, Republic of KoreaAbbreviations: ChIP, chromatin immunoprecipitation
nylindole; DLL, delta-like; DTT, dithiothreitol; ER, estr
deacetylase; NICD, Notch1 intracellular domain; PK
K376R, kinase-dead dominant negative PKCδ; PMSF, p
TPA, 12-O-tetradecanoyl-13-phorbol acetate; TSA, trich
⁎ Corresponding author at: Dept. of Life Science, Hany
Republic of Korea. Tel.: +82 2 2220 2562; fax: +82 2 2
E-mail address: incheol@hanyang.ac.kr (I. Shin).
0167-4889/$ – see front matter © 2011 Elsevier B.V. All
doi:10.1016/j.bbamcr.2011.11.005a b s t r a c ta r t i c l e i n f oArticle history:
Received 18 March 2011
Received in revised form 17 November 2011
Accepted 18 November 2011
Available online 29 November 2011
Keywords:
Notch
Transcription
Protein Kinase CδProtein kinase Cδ (PKCδ) plays a signiﬁcant role in the regulation of growth, apoptosis, and differentiation in a
diversity of cell types. We investigated the effect of PKCδ on Notch1 intracellular domain (NICD)-mediated
transcription with Notch transcription reporter constructs. The results indicate that co-expression of PKCδ
down-regulated NICD-dependent transcription. Co-expression of a dominant negative PKCδ (K376R) variant
lacking kinase activity was also able to downregulate NICD-dependent transcription, suggesting that PKCδ
exerts its inhibitory effect via a kinase-independent mechanism(s). Interestingly, expression of PKCδ as
well as K376R induced NICD up-regulation by inhibiting proteasome-mediated degradation of NICD, indicat-
ing that NICD protein quantity is not proportional to its transcriptional activity. When the subcellular distri-
bution of NICD was investigated by both subcellular fractionation and immunocytochemistry, it was found
that PKCδ and K376R effectively impaired proper nuclear localization of NICD, possibly via a physical associ-
ation between NICD and PKCδ, which was conﬁrmed by co-immunoprecipitation experiments. Chromatin
immunoprecipitation assays revealed that both PKCδ and K376R inhibit the association of NICD with the pro-
moter region of its target gene, Hes1. Furthermore, silencing of PKCδ resulted in increased NICD nuclear local-
ization and NICD transcriptional activity in MCF-7 cells. PKCδ silencing-induced increase in anti-apoptotic
survivin could not rescue apoptosis induced by doxorubicin. The data herein indicate that PKCδ can induce
down-regulation of NICD transcriptional activity via a kinase-independent inhibition of NICD nuclear target-
ing and dissociation of NICD from target gene promoters.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
The Notch signaling pathway is a highly conserved mechanism
that plays a signiﬁcant role in the control of cell fate during various
developmental processes, including cellular proliferation, differ-
entiation and apoptotic events [1]. Notch receptors are single-pass
transmembrane proteins that contain a signal peptide, a series of
epidermal growth factor-like repeats in the extracellular domain in-
volved in ligand binding, a transmembrane domain responsible for
receptor activation, and an intracellular domain [2,3]. In Drosophila,
there is one Notch receptor (dNotch) and two associated ligands
(Delta and Serrate) [4]. Mammals possess four Notch receptors
(Notch1, Notch2, Notch3 and Notch4) [5–7], ﬁve ligands containing; DAPI, 4′,6-diamidino-2-phe-
ogen receptor; HDAC, histone
Cδ, protein kinase Cδ; PKCδ
henylmethylsulfonyl ﬂuoride;
ostatin
ang University, Seoul 133-791,
298 256.
rights reserved.the two Serrate homologs, Jagged 1 (JAG1) and Jagged 2 (JAG2)
[8,9], and three Delta-like (DLL) homologs (DLL1, 3, and 4) [10–12].
Notch signaling is initiated by ligand binding with subsequent pro-
teolytic cleavage of Notch and release of the Notch intracellular
domain (NICD) [13]. The NICD then enters the nucleus and subse-
quently associates with a DNA binding protein to assemble a complex
that activates transcription of downstream target genes including
Hes1 and Hes5 [14–17].
The Protein Kinase C (PKC) family of serine/threonine kinases
plays an important role in many cellular functions including cellular
proliferation, tumor promotion, growth regulation, cell survival and
programmed cell death [18]. The PKC family can be broadly subdi-
vided into three groups: The classical/conventional PKCs (cPKCs: α,
βI, βII, γ), which are calcium dependent and activated by diacylgly-
cerol (DAG) or 12-O-tetradecanoyl-13-phorbol acetate (TPA); the
novel PKCs (nPKCs: δ, ε, θ, μ) that are also activated by DAG or TPA
but are calcium-independent; and the atypical PKCs (aPKCs: ζ, λ)
that are calcium-independent and do not respond to DAG or TPA
[19–22]. As a member of the nPKC subfamily, PKCδ contains a C-
terminal catalytic region with two conserved domains (C3 and C4)
essential for ATP binding, catalytic activity, and substrate binding.
The N-terminus of PKCδ contains a regulatory region with an
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the twin C1 domains [23–25].
Many reports suggest that Notch-induced signaling interacts with
other major signaling pathways, such as NF-kB signaling, the caspase
3 pathway, the mitogen-activated protein kinase (MAPK) pathway,
and the phosphatidylinositol 3-kinase (PI3K)/Akt pathway [26–29].
We previously reported that Akt downregulates transcriptional
activity of NICD possibly by Akt-mediated phosphorylation of NICD
and subsequent cytosolic retention of NICD [30]. While searching
for a possible site of phosphorylation by Akt on NICD using the Net-
PhosK server (http://www.cbs.dtu.dk/services/NetPhosK) and Scan-
site (http://scansite.mit.edu), we found that two serine residues,
Ser2152 and Ser2173, may also be phosphorylated by PKC. This led
us to investigate the possible regulation of NICD transcriptional activ-
ity by PKC-dependent phosphorylation. Interestingly, we found that
PKCδ, and not the classical PKCα, PKCβI and PKCβII kinases, could
downregulate NICD transcriptional activity in a kinase-independent
manner.
2. Materials and methods
2.1. Plasmids, Vectors and siRNA nucleotides
Mouse Notch1 NICD was as described [30]. HA-tagged PKC iso-
zymes (PKCα, PKCβI, PKCβII, PKCδ), and dominant-negative forms of
PKC isozymes (PKCα, PKCβI, PKCβII, PKCδ) were kindly donated by
Dr. Su-Jae Lee (Hanyang University, Seoul, Korea). pEGFPN1-PKCδ
and dominant negative forms of pEGFPN1-PKCδwere kindly provided
by Dr. Stuart H. Yupsa (Bethesda, MD, USA). The plasmid, pBJ5-
HDAC1-Flag, was obtained from Dr. Jongbok Yoon (Yonsei University,
Seoul, Korea). The plasmid, pcDNA3-Flag-HDAC1 (H141A), was a gift
from Dr. Sung Hee Baek (Seoul National University, Seoul, Korea).
siRNA nucleotides against PKCδ and control siRNA were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
2.2. Cell culture and transfection
Two types of cells, 293 T and Cos7 (ATCC), were maintained in
Dulbecco's Modiﬁed Eagle's Medium with 10% fetal bovine serum,
50 U/ml penicillin and 50 μg/ml streptomycin (Welgene, Daegu,
Korea). Cells were incubated at 37 °C under 5% CO2 in a humidiﬁed in-
cubator. 293 T and Cos7 cells were transfected using calcium phos-
phate in HEPES buffered saline as described previously [31]. MCF-7
cells were transfected using Lipofectamine 2000 (Invitrogen, CA,
USA) according to the manufacturer's protocols.
2.3. Antibodies and reagents
PKCδ, mouse Myc-Tag (9B11), rabbit c-Jun (60A8), mouse HA-tag
(6E2), and Akt and p-Akt (Ser473) antibodies were purchased from
Cell Signaling Technology (Beverly, MA, USA). Actin (C-2), rabbit
HA-probe (Y-11), and rabbit β-tubulin (H-235), mouse Hes1 (E-5)
and survivin (D-8) antibodies were purchased from Santa Cruz Bio-
technology. The 26S proteasome inhibitor, MG132, was obtained
from Calbiochem. PKCδ siRNA and control siRNA were purchased
from Santa Cruz Biotechnology .
2.4. Reporter assays
Cells grown on 12-well plates were transfected with 1.5 μg total
DNA containing 0.5 μg reporter construct [6×Notch response ele-
ments (6×NRE-Luc); 4×CSL-Luc; HES1-Luc, gifts from Dr. Hee-Sae
Park (Chonnam National University, Korea)] and analyzed 48 h after
transfection. Dual luciferase assays were performed using the Dual-
Luciferase® Reporter Assay System (Promega, Madison, WI, USA)
according to the manufacturer's instructions.2.5. Immunoblot analysis
All cells were lysed and processed 48 h post-transfection. Trans-
fected cells were washed once with phosphate-buffered saline (PBS)
and lysed with a lysis buffer [20 mM Tris–HCl, pH 7.4, 0.1 mM
EDTA, 150 mM NaCl, 1% NP-40, 0.1% Triton X-100, 0.1% SDS, 20 mM
NaF, 1 mM Na3VO4, 1×protease inhibitor (Roche, Indianapolis, IN)].
All protein samples were resolved by 10% SDS–PAGE after boiling
10 min in SDS sample buffer. For immunoblot analysis, proteins
were electro-transferred onto nitrocellulose membranes in Tris-
glycine-methanol buffer for 2 h. The membranes were blocked with
5% skim milk in standard TBST buffer for 1 h, incubated overnight
with appropriate dilutions of primary antibody in TBST containing
5% bovine serum albumin. The membranes were then washed three
times with TBST and incubated with HRP-conjugated secondary anti-
body solution for 2 h. The blots were then visualized using the WEST-
ZOL® plus Western Blot Detection System (iNtRON Biotechnology,
Seoul, Korea).2.6. Cycloheximide decay assays
Cells were seeded at a density of 5×105 cells/well in 6-well
dishes. After 24 h, cells were treated with 20 μg/ml cycloheximide
(Sigma-Aldrich, St. Louis, MO, USA) to block further protein synthesis.
The cells were harvested at each indicated time point and subjected
to immunoblot analysis.2.7. Immunostaining
For immunostaining, 293 T cells were seeded at a density of
3×105 cells/well on glass coverslips in 6-well plates, transfected
with 4 μg total DNA (2 μg Myc-NICD and 2 μg pEGFP-N1-PKCδ or
2 μg pEGFP-N1-PKCδ K376R), and processed 48 h post-transfection.
Cells were washed with PBS, ﬁxed with 3.8% paraformaldehyde in
PBS for 10 min and permeabilized with 0.05% Triton X-100 in PBS for
10 min at ambient temperature. The ﬁxed cells were washed three
times with PBS for 5 min each and blocked with 3% skim milk in PBS
for 30 min. Primary antibody (80 μl per coverslip) was diluted in 1%
skimmilk and added to each coverslip and incubated for 1 h. The sam-
ples were then washed 3 times with PBS and incubated with 80 μl
of secondary antibody solution [anti-rabbit IgG-Cy3 (In vitrogen) in
1% skim milk in PBS]. The samples were washed three times
for 10 min with PBS, and nuclei were stained with 4′,6-diamidino-2-
phenylindole (DAPI) in the ﬁrst wash. Coverslips were mounted on
glass slides and observed by ﬂuorescence microscopy (Olympus
BX50).2.8. Cell fractionation assays
In a 100-mm dish, 293 T cells were seeded at a density of
1×106 cells and subsequently transfected with 5 μg of total DNA.
Forty-eight hours post-transfection, the cells were washed with ice
cold PBS, incubated in cytoplasmic extraction buffer [10 mM HEPES,
pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol
(DTT), 0.5 mM phenylmethylsulfonyl ﬂuoride (PMSF)]and agitated
for 10 min at 4 °C. After addition of NP-40 (ﬁnal 0.5%), the samples
were further agitated for 10 min at 4 °C. The samples were then sub-
jected to centrifugation at 13,000 rpm for 5 min. The resulting super-
natant was collected as the cytosolic fraction. Nuclear pellets were
washed three times with cold PBS and resuspended in a nuclear ex-
traction buffer (20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM EDTA,
1 mM EGTA, 1 mM DTT, 1 mM PMSF). The nuclear extracts were
agitated for 10 min at 4 °C then centrifuged at 13,000 rpm at 4 °C.
The resulting supernatants were collected as the nuclear fraction.
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For immunoprecipitation (IP), 1.0 mg total proteins in a lysis buff-
er was incubated overnight with the appropriate primary antibody
(1.0 μg/ml) at 4 °C and subsequently incubated with 30 μl of Protein
G Sepharose 4 Fast Flow 50% slurry (w/v) (GE healthcare, Piscataway,
NJ, USA) for 3 h. The immunoprecipitates were washed three times
with lysis buffer. After complete removal of the supernatant, beads
were resuspended in SDS sample buffer, boiled for 10 min, resolved
by SDS–PAGE and analyzed by immunoblot.
2.10. Chromatin immunoprecipitation (ChIP) assays
For chromatin cross-linking, 293 T cells (3×107) were harvested
and washed once with PBS followed by incubation in 1.42% formalde-
hyde for 15 min at room temperature. The cells then were lysed in
a cell lysis buffer (10 mM Tris, pH 8.0, 10 mM NaCl, 0.2% NP-40,
1×protease inhibitor). The cell lysates were centrifuged for 1 min at
12,000 g. Precipitated nuclei were treated with 200 U Micrococcal
Nuclease (New England Biolabs, Hitchin, Hertfordshire, UK), resus-
pended in nuclei lysis buffer (50 mM Tris, pH 8.0, 10 mM EDTA, 1%
SDS, 1×protease inhibitor), and diluted in IP dilution buffer (20 mM
Tris, pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.01% SDS, 1% Triton X-100,
1×protease inhibitor). The lysates were then disrupted with a sonica-
tor (2 pulses, 30 s on/60 s off at 50% amplitude) to obtain DNA frag-
ments of 200 to 500 bp in length (Dr. Hielscher, GmbH, Germany).
Digested chromatin was immunoprecipitated with Myc-tag antibody
overnight at 4 °C with rotation. The immunocomplexes were collect-
ed with Protein G Sepharose 4 Fast Flow 50% slurry (w/v) (GEFig. 1. Effect of PKCδ on Notch-dependent transcription. (A) 293 T cells transfected with My
erase reporter assays 48 h post-transfection. * pb0.05 for NICD alone vs. NICD plus PKCδ us
PKCδ K376R (kinase-dead PKCδ) and one each of the three different reporter constructs (4
48 h post-transfection. The experiments were performed in triplicates. The mean±stand
PKCδ, ** pb0.05 for NICD alone vs. NICD plus PKCδ K376R using Student's t-Test.Healthcare) for 3 h at 4 °C with rotation and washed sequentially
with washing buffer 1 (20 mM Tris, pH 8.0, 150 mM NaCl, 2 mM
EDTA, 0.1% SDS, 1% Triton X-100), once with washing buffer 2
(10 mM Tris, pH 8.0, 0.25 M LiCl, 1 mM EDTA, 1% NP-40, 1% deoxy-
cholate), once with 0.1×TE buffer (1 mM Tris, pH 7.6, 0.1 mM
EDTA), and twice with elution buffer (0.1 M NaHCO3, 1% SDS) for
5 min at each step. Eluted chromatin was reverse cross-linked over-
night in 250 mM NaCl at 65 °C and DNA extraction was performed
using phenol/chloroform and ethanol precipitation. Hes1 genes were
PCR ampliﬁed with the following primers: Fwd, 5′-CAA GAC CAA
AGC GGA AAG AA-3′, and Rev, 5′-GGA TCC TGT GTG ATC CCT AGG
C-3′.
2.11. MTT assays
Cell viability was assessed by adding 20 μl of 10 mg/ml MTT
(Sigma) to 100 μl of culture medium and incubating for 3 h at 37 °C.
After removing the medium, formazan was dissolved in dimethyl
sulfoxide (Sigma) and the optical density was measured at 590 nm
using a Multiskan EX (Thermo, Finland).
2.12. Cell cycle analysis by ﬂow cytometry after doxorubicin treatment
MCF-7 cells were transfected with PKCδ or control siRNA. Doxo-
rubicin (Calbiochem, Darnstadt, Germany) was treated at the con-
centration of 1 μM in 24 h post-transfection. After additional 24 h
of incubation, the cells were ﬁxed in 100% ice-cold methanol over-
night at −20 °C. Fixed cells were incubated with 50 μg/ml of propi-
dium iodide in PBS and 1 mg/ml RNAase in PBS for 30 min. Cellc-NICD, PKC isoforms and 6×NRE-Luc reporter constructs were subjected to dual lucif-
ing Student's t-Test. (B) 293 T cells and Cos7 cells transfected with Myc-NICD, PKCδ or
×CSL-Luc, 6×NRE-Luc and HES-Luc) were analyzed by dual luciferase reporter assays
ard deviation values were used for the plots. * pb0.05 for NICD alone vs. NICD plus
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Biosciences).
3. Results
3.1. PKCδ downregulates NICD-dependent transcription
Reporter assays were performed in 293 T cells using luciferase re-
porter constructs to investigate the effect of the PKC family (PKCα,
PKCβI, PKCβII, PKCδ) on NICD-dependent transcription using
6×NRE-Luc reporter constructs with six copies of the Notch response
element (Fig. 1A). With the exception of PKCδ, other PKC family
members did not signiﬁcantly affect NICD-dependent transcriptional
activity.
To conﬁrm the effect of PKCδ on NICD-dependent transcriptional
activity, reporter assays were performed in 293 T cells and Cos7
cells using three different reporter constructs; 4×CSL-Luc with four
copies of CSL binding sites, HES1-Luc including the promoter regionFig. 2. Upregulation and stabilization of NICD protein level by PKCδ. (A) 293 T cells transfec
levels were analyzed by immunoblot analysis. (B) 293 T cells transfected with Myc-NICD and
ysis. (C) 293 T cells were transfected with Myc-NICD and PKCδ or PKCδ K376R. After treatm
immunoblot analysis. (D) Cycloheximide decay assays were performed with 20 μg/mL cyclo
tag bands in (D) were quantiﬁed and are expressed as the percentage of each control band d
values were used for the plots. * pb0.05 for NICD alone vs. NICD plus PKCδ, ** pb0.05 for Nof Hes1, and 6×NRE-Luc. PKCδ effectively downregulated NICD-
dependent transcriptional activity in both cell lines using the three
different reporter constructs (Fig. 1B). In an attempt to determine
whether PKCδ kinase activity was required for the PKCδ-dependent
inhibition of NICD-dependent transcription, we used a kinase-dead
PKCδ (PKCδ K376R) variant, in which the lysine aminoacyl residue
at position 376 in the ATP-binding pocket was replaced with an argi-
nine residue [32]. The results in Fig. 1B show that kinase activity was
not necessary for downregulation of NICD-dependent transcription as
the PKCδ K376R variant was able to downregulate NICD-dependent
transcription.
3.2. PKCδ inhibited proteasome-mediated NICD degradation
To investigate whether downregulation of NICD-dependent tran-
scription resulted from a modulation in NICD protein level by PKCδ,
we performed immunoblot analyses in 293 T cells transfected with
Myc-NICD and PKCδ (Fig. 2A). Interestingly, we found that bothted with Myc-NICD and PKCδ or PKCδ K376R were harvested after 48 h and Myc-NICD
HA-tagged PKC isoforms were harvested after 48 h and subjected to immunoblot anal-
ent with MG132 (10 μM) or vehicle for 24 h, the cells were harvested and subjected to
heximide for the indicated time periods 48 h post-transfection. (E) The density of Myc-
ensity. The experiments were performed in triplicates. The mean±standard deviation
ICD alone vs. NICD plus PKCδ K376R using Student's t-Test.
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regulation of NICD protein level by PKCδ was PKCδ isoform-
speciﬁc, as other PKC isoforms did not drastically increase NICD
protein levels (Fig. 2B). To examine the mechanism responsible
for PKCδ-mediated up-regulation of NICD protein level, Myc-NICD
and PKCδ transfected cells were treated with the 26S proteasome
inhibitor, MG132 (Fig. 2C). Inhibition of the 26S proteasome alone
resulted in a massive increase in NICD with or without the ectopic
expression of PKCδ or PKCδ K376R. Co-expression of PKCδ did not
result in an additive increase to the MG132-induced rise in NICD
level (lane 2 vs. lane 4 or lane 6), suggesting that interference
with proteasome-mediated degradation of NICD may be the main
mechanism for up-regulation of NICD protein level by PKCδ.
When transfected cells were treated with cycloheximide to inhibit
new protein synthesis, co-expression of PKCδ and PKCδ K376R sig-
niﬁcantly enhanced stability of the NICD protein (Fig. 2D and E).
Taken together, the data suggest that PKCδ kinase-independent
up-regulation of NICD protein level might be mediated by inhibi-
tion of NICD proteasomal degradation and subsequent stabilization
of NICD.
3.3. PKCδ regulated NICD-dependent transcriptional activity in a
dose-dependent manner
We performed reporter assays in 293 T cells using luciferase re-
porter constructs to examine the PKCδ dosage effect on NICD-
dependent transcription. The results indicate that PKCδ downregu-
lated NICD-dependent transcriptional activity in a dose-dependent
manner from 0.05 to 1.0 μg (Fig. 3A). To examine whether the PKCδ
dose-dependent effect on NICD-dependent transcriptional activity
was attributable to up-regulation of NICD protein levels, increasing
amounts of PKCδ were co-transfected with NICD and 6×NRE-Luc
into 293 T cells. There was a dose-dependent decrease in NICD-
dependent transcriptional activity by PKCδ co-transfection (Fig. 3A).
In addition, the results in Fig. 3B indicate that PKCδ up-regulated
NICD protein levels in a dose-dependent manner.
3.4. Regulation of NICD-dependent transcription and protein level was
not mediated by an Akt or HDAC-dependent mechanism
We previously reported that Akt downregulates NICD-dependent
transcription [30]. To exclude the possibility that the effect of PKCδFig. 3. The dose-dependent effect of PKCδ on NICD-dependent transcriptional activity and
(0.05, 0.1, 0.5, 1.0 μg) along with NICD and 6×NRE-Luc, harvested after 48 h and analyzed
mean±standard deviation values were used for the plots. * pb0.05 for NICD plus PKCδ 0
PKCδ 0.5 μg, ** pb0.05 for NICD plus PKCδ 0.5 μg vs. NICD plus PKCδ 1.0 μg using Student
PKCδ (0.05, 0.1, 0.5, 1.0 μg), harvested 48 h post-transfection and subjected to immunobloton NICD-dependent transcription was mediated by crosstalk between
Akt and PKCδ, Akt expression constructs were co-transfected with
NICD and PKCδ (Fig. 4A). The expression of Akt was shown to down-
regulate NICD transcriptional activity as well as PKCδ (Fig. 4A, bar 3
and bar 4). Co-expression of Akt and PKCδ did not further downregu-
late NICD-dependent transcriptional activity in an additive manner
(Fig. 4A, bar 5), implying that both Akt and PKCδ share the same
mechanism inhibiting NICD-dependent transcriptional activity. An-
other possibility could be that Akt downregulated NICD-dependent
transcriptional activity to a minimal level that could not be further
decreased by PKCδ. However, the co-expression of dominant-
negative Akt with PKCδ did not rescue PKCδ-mediated down-
regulation of NICD-dependent transcriptional activity (Fig. 4A, bar
6). This indicates that PKCδ-mediated downregulation of NICD-
dependent transcriptional activity was not mediated by Akt. To fur-
ther conﬁrm that modulation of NICD transcription was not mediated
by PKCδ-dependent regulation of Akt activity, phospho-Akt level, a
hallmark of Akt activity [33], was assessed in PKCδ co-transfected
cells by immunoblot analyses. The results indicate that Akt activity
was not changed by PKCδ (Fig. 4B).
Histone deacetylase (HDAC) removes an acetyl group from
histone proteins to inhibit transcription of target genes [34]. To deter-
mine whether the regulation of PKCδ on NICD-dependent trans-
cription was controlled by a mechanism involving HDAC activity,
cells transfected with NICD were treated with trichostatin A (TSA),
an HDAC inhibitor and subjected to reporter assays (Fig. 4C). NICD-
dependent transcriptional activity was slightly increased by TSA
treatment. However, TSA treatment did not prevent downregulation
of NICD-dependent transcriptional activity by PKCδ. These results
show that regulation of NICD-dependent transcription by PKCδ is
not mediated through an HDAC-dependent mechanism. Experiments
with HDAC and dominant-negative HDAC (HDAC H141A) co-
expression also conﬁrmed that downregulation of NICD-dependent
transcription was mediated by an HDAC-independent mechanism
(Fig. 4D).
3.5. PKCδ inhibited proper nuclear localization of NICD
To investigate the mechanism by which PKCδ downregulates
NICD-dependent transcriptional activity, we examined the associa-
tion between PKCδ and NICD using co-immunoprecipitation experi-
ments. The results indicate that PKCδ directly associated with NICDNICD protein level. (A) 293 T cells were transfected with increasing amounts of PKCδ
by dual luciferase reporter assays. The experiments were performed in triplicates. The
.05 μg vs. NICD plus PKCδ 0.1 μg, ** pb0.05 for NICD plus PKCδ 0.1 μg vs. NICD plus
's t-Test. (B) 293 T cells were transfected with Myc-NICD and increasing amounts of
analysis.
Fig. 4. Regulation of NICD-dependent transcription is not mediated by Akt- or HDAC-dependent mechanism(s). (A) 293 T cells were transfected with Myc-NICD, PKCδ, Akt or
dominant-negative Akt (dnAkt) and 6×NRE-Luc for 48 h. The cell lysates were analyzed by dual luciferase reporter assays. The experiments were performed in triplicates. The
mean±standard deviation values were used for the plots. (B) 293 T cells were transfected with Myc-NICD, PKCδ or PKCδ K376R, harvested after 48 h and subjected to immunoblot
analysis. (C) 293 T cells were transfected with 6×NRE-Luc, Myc-NICD and PKCδ for 48 h, treated with 10 nM TSA or vehicle 24 h post-transfection for an additional 24 h and an-
alyzed by dual luciferase reporter assays. The experiments were performed in triplicates. The mean±standard deviation values were used for the plots. (D) The cells were trans-
fected with 6×NRE-Luc, NICD, PKCδ and HDAC1 or HDAC1 H141A as indicated, harvested after 48 h and then analyzed by dual luciferase reporter assays. The experiments were
performed in triplicates. The mean±standard deviation values were used for the plots.
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the presence of PKCδ by immunostaining. The results clearly show
that PKCδ inhibited proper nuclear localization of NICD in 293 T
cells (Fig. 5B). Cells transfected with PKCδ alone revealed that PKCδ
was found both in cytoplasm and nucleus (data not shown). Co-
expression of PKCδ K376R also caused the mislocalization of NICD.
Quantiﬁcation of the immunostaining results is shown in Fig. 5C.
We also performed immunoblot analyses of cytosolic and nuclear
subcellular fractions to conﬁrm the effect of PKCδ on NICD nuclear lo-
calization. The results again indicate that PKCδ inhibited nuclear im-
port of NICD (Fig. 5D). The results in Fig. 5D should be interpreted
carefully since the cytosolic fraction contains approximately 6 times
more protein than the nuclear fraction under subcellular fractionation
protocol employed for our study.
3.6. PKCδ inhibited association of NICD to its target gene promoter region
Since the data suggest that PKCδ negatively regulates NICD tran-
scriptional activity possibly by inducing nuclear exclusion of NICD,the next logical step was to determine the effect of PKCδ on the asso-
ciation of NICD to its target gene promoter. NICD and PKCδ co-
transfected cells were subjected to chromatin immunoprecipitation
(ChIP) assays. When PKCδ was co-expressed with NICD, the associa-
tion of Notch to its target gene Hes1 promoter was decreased as com-
pared to the sample expressing NICD alone (Fig. 6A). The results
clearly show that PKCδ inhibited the association of NICD to its target
gene promoter, and may indicate that PKCδ causes downregulation
of NICD transcriptional activity by blocking the association of NICD
with its target gene promoter.
To decide whether the declined transcriptional activity of NICD
induced by PKCδ was mainly attributable to the direct physical asso-
ciation between PKCδ and NICD and subsequent inhibition of nuclear
import or to the up-regulation of NICD protein level by PKCδ, which
might also modulate NICD transcriptional activity per se, we exam-
ined the dose-dependent effect of ectopic NICD expression on NICD
transcriptional activity (Fig. 6B). Increasing NICD protein level
resulted in up-regulation of NICD transcriptional activity at low
NICD doses up to 0.5 μg (Fig. 6B, bar 2, 3, 4 and 5). However, at higher
Fig. 5. PKCδ inhibits proper nuclear localization of NICD. (A) 293 T cells were transfected with Myc-NICD and PKCδ or PKCδ K376R for 48 h. The cell lysates were then immunopre-
cipitated with Myc-tag antibody and subjected to immunoblot analyses with PKCδ antibody. For control immunoprecipitation, normal IgG was used (IgG). (B) 293 T cells were
transfected with Myc-NICD and pEGFP-N1-PKCδ or pEGFP-N1-PKCδ K376R for 48 h. The cells were then immunostained using Myc-tag antibody (red). pEGRP-N1 empty vector
was also used as a control. PKCδ was observed by EGFP ﬂuorescence (green). Nuclei were counterstained with DAPI (blue). (C) The graph shows the percentage of cells where
NICD was localized in both the cytosol and nucleus or exclusively in the cytosol (C/N, black bars) or nucleus (N, white bars). More than 50 Myc-positive cells were counted per
sample. The experiments were performed in triplicates. The mean±standard deviation values were used for the plots. * pb0.05 for NICD alone vs. NICD plus PKCδ, ** pb0.05
for NICD alone vs. NICD plus PKCδ K376R using Student's t-Test. (D) 293 T cells transfected with Myc-NICD and PKCδ or PKCδ K376R were harvested 48 h post-transfection and
fractionated into cytoplasmic (C) and nuclear (N) fractions. Both fractions were analyzed by immunoblot analysis. The same amount (30 μg) of protein was loaded onto cytosolic
and nuclear fractions. c-jun and β-tubulin were used as markers for the nuclear and cytosolic fractions.
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with increasing NICD protein amount (Fig. 6B, bar 6, 7, 8 and 9).
When ChIP assays were performed using samples with the highest
(0.5 μg NICD) and the lowest (3 μg NICD) NICD transcriptional activi-
ty as determined from Fig. 6B, the association of NICD to its target
gene promoter was considerably decreased in the 3 μg NICD trans-
fected cells as compared to the 0.5 μg NICD transfected cells
(Fig. 6C). These results indicate that association of NICD to its target
promoter is also regulated by its own concentration. Interestingly,
when the subcellular distribution of NICD were compared between
0.5 μg NICD transfected cells and 3 μg NICD transfected cells
(Fig. 6D), it appeared that signiﬁcant portion of NICD showed cytosol-
ic mislocalization in 3 μg NICD transfected cells. This paradoxical in-
verse relationship between NICD transcriptional activity and its
protein level may suggest that a minimal amount of NICD protein is
sufﬁcient for maximum NICD transcriptional activity, and increases
in NICD protein concentration above the optimum level may interfere
with its transcriptional activity. Taken together, these data indicate
that the inhibitory effect of PKCδ on NICD transcriptional activity
might result from the combined effect of both PKCδ-mediated nuclear
exclusion of NICD and/or accumulation of NICD protein above a
threshold level.3.7. Silencing of PKCδ decreased cell proliferation and survival in MCF-7
human breast cancer cells
Next, we further conﬁrmed the effect of PKCδ on Notch signaling
using MCF-7 human breast cancer cell line. As indicated in Fig. 7A,
transfection of PKCδ siRNA resulted in a dose-dependent decrease
of PKCδ expression. Accordingly, we could observe the dose-
dependent increase in levels of Hes1 and survivin, well known intra-
cellular targets of Notch [35,36]. We also observed that silencing of
PKCδ resulted in a decrease in cytosolic endogenous NICD and in-
crease in nuclear endogenous NICD, which are in accordance with
previous ﬁndings with 293 T cells in which forced expression of
PKCδ resulted in attenuated nuclear localization of NICD. Interesting-
ly, when almost complete knock-out of PKCδ was achieved by using
5 μg of siRNA per dish, we observed decrease in total level of NICD
as well as nuclear level of NICD. These data might support the idea
that minimal amount of PKCδ may be required to stabilize NICD
(Fig. 2). The reporter assay in Fig. 7C indicates that silencing of PKCδ
increased NICD-dependent transcriptional activity in MCF-7 cells, fur-
ther supporting the previous ﬁnding that PKCδ negatively regulated
transcriptional activity of NICD. When the effect of PKCδ silencing
on cell proliferation and apoptosis was examined, the silencing of
Fig. 6. PKCδ inhibits the association of NICD to its target gene promoter. (A) 293 T cells were transfected with Myc-NICD and PKCδ or PKCδ K376R for 48 h. ChIP assays were per-
formed as described in the Materials and Methods. (B) 293 T cells were transfected with increasing amounts of NICD (0, 0.05, 0.1, 0.25, 0.5†, 1.0, 2.0, 2.5, and 3.0‡ μg) along with
6×NRE-Luc and analyzed by dual luciferase reporter assays 48 h post-transfection. The dagger (†) and double dagger (‡) denote the highest and lowest NICD transcriptional activ-
ities measured, respectively. The experiments were performed in triplicates. The mean±standard deviation values were used for the plots. * pb0.05 for NICD 0.5 μg vs. NICD 3.0 μg
using Student's t-Test. (C) 293 T cells were transfected with either 0.5† or 3.0‡μg Myc-NICD and then ChIP assays were performed. (D) 293 T cells were transfected with either 0.5†
or 3.0‡ μg Myc-NICD. The transfected cells were subjected to subcellular fractionation. The same amount (30 μg) of protein was loaded onto cytosolic and nuclear fractions. c-jun
and β-tubulin were used as markers for the nuclear and cytosolic fractions.
394 M. Kim et al. / Biochimica et Biophysica Acta 1823 (2012) 387–397PKCδwas shown to decrease cell proliferation as indicated by MTT as-
says (Fig. 7D). When cell cycle proﬁles of control and PKCδ silenced
cells were performed, we observed that silencing of PKCδ induced a
slight decrease in S-phase fraction of cells (Fig. 7E). Furthermore,
when apoptosis was induced by doxorubicin treatment, we observed
a huge reduction in S-phase as well as a big increase in subG1 apopto-
tic fraction of cells. These results indicate that silencing of PKCδ
reduced proliferation of breast cancer cells and increased apoptosis
of the cells upon treatment with doxorubicin, possibly via down-
regulation of PKCδ activity and/or subsequent up-regulation of
Notch-downstream effects.4. Discussion
In this report, we examined the effect of PKC isoforms on NICD
(Notch1)-dependent transcription. Among members of the PKC iso-
forms tested, only PKCδ down-regulated NICD-dependent transcrip-
tion in a kinase-independent manner. Although Notch signaling has
been reported to interact with other signaling molecules, especially
with protein kinases including MAPK, Akt, and glycogen synthase ki-
nase 3β [28,29,37], only a few reports have described the crosstalk
between Notch and PKC signaling. For example, PKC-mediated phos-
phorylation of HES-1, a basic helix-loop-helix DNA binding protein,
the expression of which was induced by NICD [38], resulted in up-
regulation of lipocalin-type prostaglandin D synthase through dere-
pression of Notch-Hes signaling in human medulloblastoma cells
[39]. Ström et al. [40] also reported that PKC-mediated phosphoryla-
tion of HES-1 and subsequent inhibition of HES-1 DNA binding activ-
ity is required for neurite outgrowth in PC12 cells. These reports
indicate that PKC may affect Notch down-stream signaling via post-transcriptional modiﬁcation of HES-1, but the direct crosstalk be-
tween PKC and Notch1 has not yet been elucidated.
Our results in this report indicate that PKCδ could lead to down-
regulation of NICD-dependent transcription via interaction with NICD
as determined by co-immunoprecipitation experiments (Fig. 5A), inhibi-
tion of NICD nuclear import (Figs. 5B–D and 7B) and reduced association
of NICD to its target gene promoter (Fig. 6). Interestingly, PKCδ kinase ac-
tivity was not responsible for these phenomena since the kinase-dead
PKCδ K376R variant showed the same effect as wild-type PKCδ and
NICD mutants in which two possible PKC phosphorylation sites (Ser
2152 and Ser 2173) were replaced with alanine, were also inhibited by
PKCδ (data not shown). Paradoxically, while PKCδ down-regulated
NICD-dependent transcriptional activity, NICD protein levels were in-
creased by PKCδ (Figs. 1 and 2A). Our data shown in Fig. 2 indicate that
the up-regulation of NICD protein level by PKCδ might be a result of
inhibited proteasome-mediated degradation and stabilization of NICD.
It recently became clear that proteasome-mediated protein degra-
dation of nuclear receptors and co-activators plays an important role
in eukaryotic transcriptional activity and is required for efﬁcient tran-
scriptional activity (as reviewed in [41]). We show that accumulation
of NICD protein by PKCδ-mediated inhibition of proteasome-
mediated degradation may not efﬁciently associate with its target
gene promoter. Indeed, we found that association of NICD to its target
gene promoter was severely perturbed upon PKCδ co-expression as
revealed by ChIP assays, although NICD protein level was markedly
increased by PKCδ (Figs. 2 and 6). This is because accumulated NICD
protein induced by PKCδ interrupts the effective association of NICD
to its target gene promoter. We also previously reported that Akt-
mediated stabilization of estrogen receptor alpha (ERα) can inhibit
the efﬁcient turnover of ERα, which is a necessary requirement to
maintain an active ERα transcription complex [42].
Fig. 7. Silencing of PKCδ decreased cell proliferation and survival in MCF-7 human breast cancer cells. (A) Silencing of PKCδ expression by siRNA in MCF-7 cells. MCF-7 cells were
transfected with PKCδ siRNA (1, 2 and 5 μg) and control siRNA (5 μg) by Lipofectamine 2000 according to the manufacturer's protocols. The cells were subjected to immunoblot
analyses with PKCδ, Hes1 and surviving antibodies. (B) MCF-7 cells transfected with PKCδ siRNA were harvested 72 h post transfection and fractionated into cytoplasmic and nu-
clear fractions. Both fractions were analyzed by immunoblot analyses. The same amount (30 μg) of protein was loaded onto cytosolic and nuclear fractions. c-jun and β-tubulin
were used as markers for the nuclear and cytosolic fractions. (C) MCF-7 cells transfected with PKCδ siRNA were subjected to MTT assays at each indicated time points (*
pb0.05, ** pb0.005, *** pb0.0005). (D) MCF-7 cells transfected with PKCδ siRNA (5 μg) were treated with doxorubicin (1 μM) for 24 h. The cells were then ﬁxed in methanol
and incubated in PBS containing 50 μg/ml propidium iodide and 1 mg/ml RNase. Propidium iodide-labeled nuclei were analyzed by ﬂow cytometry. The DNA histograms were
represented as bar graph from three independent experiments (* pb0.05, ** pb0.005).
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radation, there are some reports indicating that the ubiquitin-
proteasome pathway may regulate NICD activity [43]. Öberg et al.
[44] reported that the mammalian Sel-10 homolog physically inter-
acts with NICD, inducing ubiquitination of NICD near the PEST do-
main. In addition, Sel-10 reduces NICD transcriptional activity.
They also showed that blocking Sel-10-mediated degradation by
MG132 results in a decrease of HES1-luciferase reporter activity
with a concomitant increase in the amount of NICD. The authors
concluded that ubiquitinated NICD is a less potent activator of tar-
get gene transcription. Gupta-Rossi et al. also reported that Sel-10binds only to the hyperphosphorylated form of NICD by experi-
ments using λ phosphatase to dephosphorylate NICD in vitro [45].
They concluded that Sel-10 is involved in the down-regulation of
Notch by proteasome-mediated degradation of the active Notch
transcriptional complex after a phosphorylation event in the nucle-
us. Although PKCδ kinase activity was not shown to be involved in
the down-regulation of NICD transcriptional activity and up-
regulation of NICD protein level in our study, we also tested wheth-
er co-expression of PKCδ could affect the association of Sel-10 with
NICD. It appeared that PKCδ did not affect the association between
Sel-10 and NICD nor did it modulate Sel-10 level (data not shown),
396 M. Kim et al. / Biochimica et Biophysica Acta 1823 (2012) 387–397suggesting that PKCδ did not regulate the association between Sel-
10 and NICD.
Using MCF-7 human breast cancer cells, we have also conﬁrmed
that endogenous PKCδ was also responsible for the down-regulation
of Notch transcriptional activity (Fig. 7A–C). Interestingly, silencing
of PKCδ and subsequent up-regulation of Notch transcriptional activ-
ity resulted in decreased cell proliferation and increased susceptibility
to doxorubicin-induced apoptosis in MCF-7 cells (Fig. 7D and E). In-
deed, it has been previously reported that PKCδ enhances prolifera-
tion and survival of mammary cells [46] and promotes resistance to
chemotherapeutics in lung cancer cells [47]. Notch signaling was
also shown to inhibit proliferation of endothelial cells [48] and hema-
topoietic progenitor cells [49] and induce apoptosis of esophageal
squamos cancer cells [50], B cells [51] and hepatocellular carcinoma
cells [52]. In contrast to these ﬁndings, Notch signaling was also
reported to inhibit apoptosis via expression of anti-apoptotic protein
survivin [36]. In our experiment, survivin was also effectively induced
by PKCδ silencing-induced Notch activity (Fig. 7A). Currently, we do
not know whether silencing of PKCδ alone was sufﬁcient or subse-
quent up-regulation of Notch transcriptional activity was also re-
quired to sensitize MCF-7 cells to doxorubicin-induced apoptosis.
However, it is clear that Notch-induced survivin failed to attenuate
doxorubicin-triggered apoptosis further enhanced by PKCδ-silencing
or other Notch downstream factor.
Based on our data herein, we can conclude that PKCδ down-
regulates NICD transcriptional activity via twomechanisms; ﬁrst, it in-
creases NICD protein level possibly resulting in an accumulation of an
inactive form of NICD, and/or it results in nuclear exclusion of NICD by
physical association with PKCδ. Indeed, although around 80% of PKCδ
co-expressing cells showed increased cytosolic localization of NICD
(Fig. 5B), the remaining 20% of the PKCδ co-expressing cells still
showed exclusive nuclear localization of NICD. Therefore, we specu-
late that PKCδmay inhibit NICD transcriptional activity by nuclear ex-
clusion of NICD in cells showing cytosolic localization of NICD and by
possible accumulation of inactive form of NICD in cells showing nucle-
ar localization of NICD. Further investigation is required to determine
how the two distinct mechanisms of PKCδ-induced down-regulation
of NICD transcription cooperate in the heterogenous population of
cells needs further investigation.
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